Stanozolol (Winstrol)
Stanozolol, commonly known by the trade name Winstrol, is a 17-alpha-alkylated anabolic steroid derived from dihydrotestosterone (DHT). It is characterised by high anabolic and low androgenic activity — which makes it a go-to choice for athletes chasing lean muscle mass, strength, and definition without the heavier androgenic side effects.
Originally developed in 1962 by Sterling-Winthrop Laboratories, Stanozolol was first introduced for its therapeutic potential. Early studies pointed to effects on immune system modulation — raising lymphocyte counts and CD8+ cell levels, while lowering CD3+ and CD4+ markers — which hinted at a possible role in autoimmune conditions and immunomodulatory therapy, particularly for postmenopausal women with osteoporosis.
Medically, Stanozolol has been approved for the treatment of hereditary angioedema, a rare genetic condition that triggers episodes of swelling in various parts of the body. It also appears to influence certain immunological processes, though its clinical use in immunotherapy remains limited.
Key Highlights
-
Highly anabolic, with minimal water retention
-
Derived from DHT; non-aromatising — so there is no conversion to oestrogen
-
Clinically used in hereditary angioedema treatment
-
Early research suggests potential immune-modulating effects
-
Improves muscle hardness, vascularity, and definition — a reason it is popular in cutting cycles
Considerations
-
Hepatotoxic because of 17-alpha-alkylation; cycle length should be kept short and liver support is advised
-
May negatively impact lipid profile (e.g. lower HDL, raised LDL)
-
Can cause joint dryness or discomfort as a knock-on of low water retention
-
Post-cycle therapy (PCT) may be needed to restore hormonal balance








Reviews
There are no reviews yet